Establishment of Animal Models of Dementia with Neuropeptides and Development Study of Anti-Dementia Drugs
Establishment of Animal Models of Dementia with Neuropeptides and Development Study of Anti-Dementia Drugs
批准号:
09672261
负责人:
UKAI Makoto
金额:
$1.02万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1998
中文摘要
1.Galanin shortened step-down latency of passive avoidance learning,while the dopamine D - 21 D2 receptor agonist SKF38393the dopamine D - 22 D2 receptor agonist RU24213,the dopamine D - 21 D - 2 receptor antagonist SCH23390 or the dopamine D - 22 D - 2 receptor antagonistS(-)-sulpiride failed to influence it. Dynorphin A-(1-13) and SKF38393 markedly improved thegalanin-induced shortening of step-down latency. However, RU24213,SCH23390 or S(-)-sulpiride did not affect the galanin-induced shortening of step-down latency.Theeffects of intracerebroventricular administration of δ D21 D2- and δ D22 D2-selective opioidreceptor agonists on spontaneous alternation performance,elevated plus-maze behavior and passive avoidance learning including step-down and step-throughtypes were examined in mice. Although the δ d -selective opioid receptor agonist,[D-Pen - D12 - D1,L-Pen - D15 - D1] enkephalin (DPLPE) or the δ - D22 -selective opioid receptor agonist,[D-Ala] delto…rphin II (deltorphin)不明确影响spontaneous alternation performance orelevated plus-maze behaviorDPLPE和deltorphin inhibited passive avoidance learning including step-down and step-throughtypes. The δ d -selective opioid receptor antagonist, 7-benzylidenenaltrexone,D22 -selective opioid receptor antagonist, naltriben,significantly antagonized the inhibitory effects of DPLPE and deltorphin on passive avoidancelearning, respectively. In contrast,DPLPE or deltorphin did not markedly influence behavioral responses induced by electroshocks duringtraining of passive avoidance learning.3.The present study was designed to clarify whether opioidneuronal systems are involved in the beneficial effects of tachykinins such as the neurokininNK - D21 - D2 receptor agonist, substance P(SP), the neurokinin NK - D22 - D2 receptor agonist,neurokinin A(NKA), and the neurokinin NK D23 - D2 receptor agonist, senktide,on the scopolamine-induced impairment of spontaneous alternation performance in mice.Intracerebroventricular injections of SP,NKA and senktide inhibited the scopolamine-induced impairment of spontaneous alternation performancewithout influencing total arm实体indicating the antiamnesic effects of tachykinins. Furthermore, the inhibitory effects of SP,but not those of NKA or senktide,were almost completely reversed by pretreatment with naloxone. However,the effects of SP on the scopolamine-induced impairment of spontaneous alternation performance werenot influenced by pretreatment with the μ-opioid receptor antagonist, β-funaltrexaminethe δ-opioid receptor antagonist, naltrindole, and the κ-opioid receptor antagonist,nor-binaltorphimine . less
英文摘要
1.Galanin shortened step-down latency of passive avoidance learning, while the dopamine DィイD21ィエD2 receptor agonist SKF38393, the dopamine DィイD22ィエD2 receptor agonist RU24213, the dopamine DィイD21ィエD2 receptor antagonist SCH23390 or the dopamine DィイD22ィエD2 receptor antagonist S(-)-sulpiride failed to influence it. Dynorphin A-(1-13) and SKF38393 markedly improved the galanin-induced shortening of step-down latency. However, RU24213, SCH23390 or S(-)-sulpiride did not affect the galanin-induced shortening of step-down latency.The effects of intracerebroventricular administration of δィイD21ィエD2- and δィイD22ィエD2-selective opioid receptor agonists on spontaneous alternation performance, elevated plus-maze behavior and passive avoidance learning including step-down and step-through types were examined in mice. Although the δィイD21ィエD2-selective opioid receptor agonist, [D-PenィイD12ィエD1, L-PenィイD15ィエD1] enkephalin (DPLPE) or the δィイD22ィエD2-selective opioid receptor agonist, [D-AlaィイD12ィエD1] delto … More rphin II (deltorphin) did not markedly affect spontaneous alternation performance or elevated plus-maze behavior, DPLPE and deltorphin inhibited passive avoidance learning including step-down and step-through types. The δィイD21ィエD2-selective opioid receptor antagonist, 7-benzylidenenaltrexone, and the δィイD22ィエD2-selective opioid receptor antagonist, naltriben, significantly antagonized the inhibitory effects of DPLPE and deltorphin on passive avoidance learning, respectively. In contrast, DPLPE or deltorphin did not markedly influence behavioral responses induced by electroshocks during training of passive avoidance learning.3.The present study was designed to clarify whether opioid neuronal systems are involved in the beneficial effects of tachykinins such as the neurokinin NKィイD21ィエD2 receptor agonist, substance P(SP), the neurokinin NKィイD22ィエD2 receptor agonist, neurokinin A(NKA), and the neurokinin NKィイD23ィエD2 receptor agonist, senktide, on the scopolamine-induced impairment of spontaneous alternation performance in mice. Intracerebroventricular injections of SP, NKA and senktide inhibited the scopolamine-induced impairment of spontaneous alternation performance without influencing total arm entries, indicating the antiamnesic effects of tachykinins. Furthermore, the inhibitory effects of SP, but not those of NKA or senktide, were almost completely reversed by pretreatment with naloxone. However, the effects of SP on the scopolamine-induced impairment of spontaneous alternation performance were not influenced by pretreatment with the μ-opioid receptor antagonist, β-funaltrexamine, the δ-opioid receptor antagonist, naltrindole, and the κ-opioid receptor antagonist, nor-binaltorphimine. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Makoto Ukai: "Dopaminergic involvement in improving effects of dynorphin A-(1-13) on galanin-induced impairment of passive avoidance learning in mice" Human Psychopharmacology. 12. 243-248 (1997)
Makoto Ukai:“多巴胺能参与改善强啡肽 A-(1-13) 对甘丙肽诱导的小鼠被动回避学习损伤的影响”人类精神药理学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Makoto Ukai: "Dopaminergic involvement in improving effects of dynorphin A-(1-13) on galanin-induced impairment of passive avoidance learning in mice"Human Psychopharmacology. 12. 243-248 (1997)
Makoto Ukai:“多巴胺能参与改善强啡肽 A-(1-13) 对甘丙肽诱导的小鼠被动回避学习损伤的影响”人类精神药理学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
鵜飼 良: "神経行動薬理学研究の最前線"J. R. Prous S. A. Publishers. 7 (1997)
Ryo Ukai:“神经行为药理学研究的前沿”J. R. Prous S. A. Publishers 7 (1997)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
鵜飼 良: "生理活性ペプチドによるアルツハイマー型痴呆治療薬の開発研究" 名城大学総合研究所紀要. 2. 75-79 (1997)
Ryo Ukai:“使用生物活性肽研究和开发阿尔茨海默氏型痴呆治疗药物” 名城大学研究所公告 2. 75-79 (1997)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
鵜飼 良: "疼痛治療の現状と展望"ミクス. 12 (1998)
Ryo Ukai:“疼痛治疗的现状和前景”Mix 12 (1998)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 27 条
Development of novel therapeutic drugs for Alzheimer disease
-
批准号:14572081
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:2002
-
负责人:UKAI Makoto
-
依托单位:
Developmental study on anti-dementia drugs by using neuropeptides related to memory disturbance
-
批准号:11672197
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:1999
-
负责人:UKAI Makoto
-
依托单位:
Development study of preventive and therapeutic drugs for Alzheimertype senile dementia by using biologically active peptides
-
批准号:07672396
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.09万
-
财政年份:1995
-
负责人:UKAI Makoto
-
依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
-
批准号:81000622
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:梁胜
-
依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
-
批准号:31060293
-
项目类别:地区科学基金项目
-
资助金额:26.0万元
-
批准年份:2010
-
负责人:郭亚芬
-
依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
-
批准号:30960334
-
项目类别:地区科学基金项目
-
资助金额:22.0万元
-
批准年份:2009
-
负责人:董贵成
-
依托单位: